icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

Is Eli Lilly Stock a Buy Right Now? A Deep Dive into Growth and Risks

Samuel ReedSaturday, Apr 19, 2025 4:36 pm ET
41min read

Eli Lilly (NYSE: LLY) has emerged as a leader in the booming diabetes and obesity drug markets, thanks to its blockbuster therapies like Mounjaro and Zepbound. But with rising competition, regulatory pressures, and high valuations, investors are asking: Is this stock still worth buying? Let’s dissect the data to find out.

Recent Financial Performance: Strong, but Not Without Hurdles

Eli Lilly’s Q1 2025 results, released in early May, are expected to show $7.2 billion in revenue, a 5.8% increase from Q1 2024. Analysts project an EPS of $4.72, driven by continued demand for its GLP-1 receptor agonists. However, 2024 was a mixed year:
- Total 2024 revenue hit $45 billion, up 32% year-over-year, but missed initial guidance by $400 million due to supply chain bottlenecks and slower-than-expected adoption of Zepbound.
- Q4 2024 revenue reached $13.5 billion, with Mounjaro contributing $3.5 billion and Zepbound $1.9 billion.

LLY Trend

The stock has surged 33% in 2024, but volatility persists. A 14.5% jump in April 2025 followed positive late-stage trial results for orforglipron, an oral weight-loss drug that could reshape the market.

Key Products: Dominance in Diabetes and Obesity


- Mounjaro (semaglutide): Generated over $5 billion in 2024, treating both diabetes and obesity. Its dominance faces pressure from European price negotiations and competition from Novo Nordisk’s Wegovy, but global expansion (e.g., China) offers growth.
- Zepbound (daptafermin): Despite slower adoption due to high costs ($3,500 annually) and logistical hurdles, Q4 sales hit $1.9 billion. Management is exploring cost-sharing programs to boost uptake.
- Orforglipron (new oral therapy): The star of 2025. Phase 3 trial results showed 16 lbs of weight loss and a safe profile, positioning it to rival injectables. Analysts project peak sales of $11.8 billion by 2030.

Strategic Initiatives: R&D and Manufacturing

  • R&D Investment: Lilly spent $3.1 billion (18% of revenue) in 2024, focusing on genetic medicines (e.g., sickle cell anemia treatments) and oncology therapies like Verzenio.
  • Manufacturing Expansion: Plans to boost GLP-1 production by 60% in 2025 aim to address past supply constraints. CEO David Ricks emphasized scalability as critical to meeting demand.

Risks and Challenges

  1. Pricing and Regulation:
  2. U.S. inflation-reduction policies and European price caps could compress margins.
  3. The DOJ is investigating drug pricing practices, alongside peers like Novo Nordisk.
  4. Competition:
  5. Novo Nordisk’s Wegovy and Ozempic dominate the injectable market.
  6. Pfizer’s withdrawal of danuglipron (due to liver toxicity) reduced competition, but rivals like Viking Therapeutics’ VK2735 loom.
  7. Operational Risks:
  8. Supply chain delays or quality issues could disrupt therapy distribution.
  9. Clinical trial delays in genetic medicines (e.g., imlunestrant) might postpone revenue.

NVO, LLY Closing Price

While LLY has outperformed NVO in 2025, the rivalry remains fierce.

Analyst Ratings and Price Targets

Analysts remain cautiously optimistic:
- Consensus Rating: "Moderate Buy" with an average price target of $1,012 (20% upside from April 2025 levels).
- Bullish View: Citigroup sees $1,190, citing LLY’s leadership in diabetes and oncology.
- Cautious Take: Morgan Stanley trimmed its target to $1,124, citing valuation concerns.

Conclusion: A Buy with Caution

Eli Lilly’s stock is a buy for long-term investors, but risks demand attention:
- Upside Drivers:
- Orforglipron’s FDA approval (expected late 2025) could supercharge growth.
- 2025 revenue guidance of $58–61 billion implies 32% growth, fueled by Mounjaro, Zepbound, and oncology drugs.
- R&D pipeline: Genetic medicines and oncology therapies position LLY for future markets.
- Downside Risks:
- High valuations (P/E of 71.88, vs. S&P 500’s 22) may limit short-term gains.
- Regulatory headwinds and pricing pressures could cap margins.

Final Take: With $11.8 billion in projected orforglipron sales by 2030 and a diversified pipeline, Eli Lilly’s long-term prospects are strong. However, investors should monitor Q2 2025 updates on supply chain improvements and competitive dynamics. For those willing to weather volatility, LLY offers a compelling growth story in a high-demand therapeutic space.

LLY Total Revenue YoY, Total Revenue

The data tells a story of sustained momentum—provided the company navigates its challenges.

Comments

Add a public comment...
Post
User avatar and name identifying the post author
Shinoskay9
04/19
LLY's orforglipron could moon if FDA approval happens. Fingers crossed for those betting on this pipeline gem.
0
Reply
User avatar and name identifying the post author
iahord
04/19
@Shinoskay9 Do you think LLY can maintain growth post-2030?
0
Reply
User avatar and name identifying the post author
CaseEnvironmental824
04/19
Mounjaro's global expansion could be a game-changer. Diabetes market is huge and growing.
0
Reply
User avatar and name identifying the post author
bigbear0083
04/19
Zepbound's high cost might hurt adoption, but cost-sharing programs could help stabilize sales.
0
Reply
User avatar and name identifying the post author
Howell--Jolly
04/19
Valuation high, but growth potential is strong.
0
Reply
User avatar and name identifying the post author
HobbyLegend
04/19
@Howell--Jolly Valuation's steep, but LLY's pipeline solid. Growth might offset high P/E.
0
Reply
User avatar and name identifying the post author
lies_are_comforting
04/19
Pfizer's danuglipron exit opened space for rivals. VIKing's VK2735 might give LLY a run for its money soon.
0
Reply
User avatar and name identifying the post author
Local-Store-491
04/19
LLY's Q2 update will be crucial. Supply chain improvements and competitive dynamics to watch closely.
0
Reply
User avatar and name identifying the post author
Solarprobro4
04/19
R&D pipeline looks solid, but high valuations might limit short-term gains. Long-term hold maybe?
0
Reply
User avatar and name identifying the post author
Qwazarius
04/19
Zepbound's high cost might slow adoption, but cost-sharing programs could boost uptake. Lilly's exploring options, right?
0
Reply
User avatar and name identifying the post author
Wise-Interest3001
04/19
@Qwazarius Yeah, LiLLY's on it.
0
Reply
User avatar and name identifying the post author
SomeSortOfBrit
04/19
LLY's R&D pipeline is 🔥
0
Reply
User avatar and name identifying the post author
Lurking_In_A_Cape
04/19
Mounjaro's global expansion is a goldmine. But European price talks might pinch margins. Watch that space.
0
Reply
User avatar and name identifying the post author
investortrade
04/19
LLY vs. NVO rivalry is heating up. Who'll dominate the diabetes market? The game is far from over.
0
Reply
User avatar and name identifying the post author
shakenbake6874
04/19
Orforglipron's approval could be a game-changer.
0
Reply
User avatar and name identifying the post author
cyarui
04/19
@shakenbake6874 What's your take on LLY's pipeline?
0
Reply
User avatar and name identifying the post author
Imgoatedp2
04/19
@shakenbake6874 Totally agree, orforglipron's potential is huge.
0
Reply
User avatar and name identifying the post author
RamBamBooey
04/19
I'm holding a modest LLY position. Diversifying with $AAPL and $TSLA for balance. Anyone else playing it safe?
0
Reply
User avatar and name identifying the post author
DrSilentNut
04/19
Orforglipron's weight loss results are 🔥. LLY's pipeline got me hyped for future gains.
0
Reply
User avatar and name identifying the post author
floorborgmic
04/19
Supply chain delays are a silent killer. Lilly needs to nail production to avoid distribution headaches.
0
Reply
User avatar and name identifying the post author
LoinsSinOfPride
04/19
@floorborgmic True, supply chain issues can wreck a stock's run. Lilly needs to hit production targets or face distribution drama.
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App